NR 568 Final Exam Advanced Pharmacology Adult-Gerontology Primary Care NP
Actual Exam 2026-2027- 100% Verified Detailed Rationales - Pass Guaranteed -
A+ Graded - 147 Questions with Answers.....
NR 568 Advanced Pharmacology AGPCNP Final Exam Practice Questions (180
Questions)
SECTION A: PHARMACOKINETICS & PHARMACODYNAMICS
1. A patient with hepatic cirrhosis has reduced ability to metabolize drugs via
Phase I reactions. Which drug would be MOST affected?
A) Lorazepam (primarily Phase II glucuronidation)
B) Phenytoin (primarily Phase I oxidation)
C) Morphine (primarily Phase II conjugation)
D) Acetaminophen (primarily Phase II sulfation)
Answer: B) Phenytoin
Rationale: Phase I reactions (oxidation, reduction, hydrolysis) are mediated by
CYP450 enzymes in the liver and are significantly impaired in cirrhosis. Phenytoin
is metabolized via CYP2C9/2C19 oxidation. Lorazepam, morphine, and
,acetaminophen undergo Phase II conjugation, which is generally preserved in liver
disease .
2. A patient with low serum albumin is prescribed warfarin. What effect should
the NP anticipate?
A) Decreased free drug levels and reduced anticoagulant effect
B) Increased free drug levels and increased anticoagulant effect
C) No change because albumin binding is irrelevant
D) Increased binding to alpha-1 acid glycoprotein
Answer: B) Increased free drug levels and increased anticoagulant effect
Rationale: Low albumin increases the free fraction of highly protein-bound drugs
(warfarin is 99% bound). This increases pharmacologic effect and toxicity risk.
Sulfonamides can displace warfarin from albumin, further increasing bleeding risk
.
,3. A drug that is a weak base (pKa 8.5) is administered. Which intervention would
INCREASE its renal excretion?
A) Alkalinizing the urine (increasing pH)
B) Acidifying the urine (decreasing pH)
C) Increasing urine flow rate only
D) Decreasing urine flow rate
Answer: B) Acidifying the urine (decreasing pH)
Rationale: Weak bases are ionized (trapped) in acidic urine, enhancing excretion.
Weak acids are better excreted in alkaline urine (ion trapping). This follows the
principle: "ionized drugs are trapped and excreted" .
4. A patient receiving a high extraction ratio drug (e.g., propranolol) develops
heart failure. What effect on oral bioavailability should the NP anticipate?
A) Decreased bioavailability due to reduced hepatic blood flow
, B) Increased bioavailability due to reduced first-pass metabolism
C) No change because bioavailability is independent of blood flow
D) Decreased bioavailability due to increased protein binding
Answer: B) Increased bioavailability due to reduced first-pass metabolism
Rationale: High extraction ratio drugs have bioavailability limited by hepatic blood
flow. Heart failure reduces hepatic blood flow, decreasing first-pass metabolism
and increasing oral bioavailability. This can lead to toxicity at standard doses .
5. A patient is switched from immediate-release to extended-release formulation
of the same drug. Which pharmacokinetic parameter is MOST likely to change?
A) Time to peak concentration (Tmax)
B) Volume of distribution (Vd)
C) Half-life (t½)
Actual Exam 2026-2027- 100% Verified Detailed Rationales - Pass Guaranteed -
A+ Graded - 147 Questions with Answers.....
NR 568 Advanced Pharmacology AGPCNP Final Exam Practice Questions (180
Questions)
SECTION A: PHARMACOKINETICS & PHARMACODYNAMICS
1. A patient with hepatic cirrhosis has reduced ability to metabolize drugs via
Phase I reactions. Which drug would be MOST affected?
A) Lorazepam (primarily Phase II glucuronidation)
B) Phenytoin (primarily Phase I oxidation)
C) Morphine (primarily Phase II conjugation)
D) Acetaminophen (primarily Phase II sulfation)
Answer: B) Phenytoin
Rationale: Phase I reactions (oxidation, reduction, hydrolysis) are mediated by
CYP450 enzymes in the liver and are significantly impaired in cirrhosis. Phenytoin
is metabolized via CYP2C9/2C19 oxidation. Lorazepam, morphine, and
,acetaminophen undergo Phase II conjugation, which is generally preserved in liver
disease .
2. A patient with low serum albumin is prescribed warfarin. What effect should
the NP anticipate?
A) Decreased free drug levels and reduced anticoagulant effect
B) Increased free drug levels and increased anticoagulant effect
C) No change because albumin binding is irrelevant
D) Increased binding to alpha-1 acid glycoprotein
Answer: B) Increased free drug levels and increased anticoagulant effect
Rationale: Low albumin increases the free fraction of highly protein-bound drugs
(warfarin is 99% bound). This increases pharmacologic effect and toxicity risk.
Sulfonamides can displace warfarin from albumin, further increasing bleeding risk
.
,3. A drug that is a weak base (pKa 8.5) is administered. Which intervention would
INCREASE its renal excretion?
A) Alkalinizing the urine (increasing pH)
B) Acidifying the urine (decreasing pH)
C) Increasing urine flow rate only
D) Decreasing urine flow rate
Answer: B) Acidifying the urine (decreasing pH)
Rationale: Weak bases are ionized (trapped) in acidic urine, enhancing excretion.
Weak acids are better excreted in alkaline urine (ion trapping). This follows the
principle: "ionized drugs are trapped and excreted" .
4. A patient receiving a high extraction ratio drug (e.g., propranolol) develops
heart failure. What effect on oral bioavailability should the NP anticipate?
A) Decreased bioavailability due to reduced hepatic blood flow
, B) Increased bioavailability due to reduced first-pass metabolism
C) No change because bioavailability is independent of blood flow
D) Decreased bioavailability due to increased protein binding
Answer: B) Increased bioavailability due to reduced first-pass metabolism
Rationale: High extraction ratio drugs have bioavailability limited by hepatic blood
flow. Heart failure reduces hepatic blood flow, decreasing first-pass metabolism
and increasing oral bioavailability. This can lead to toxicity at standard doses .
5. A patient is switched from immediate-release to extended-release formulation
of the same drug. Which pharmacokinetic parameter is MOST likely to change?
A) Time to peak concentration (Tmax)
B) Volume of distribution (Vd)
C) Half-life (t½)
